EndoFectin Max
Introducing EndoFectin™ Max
| EndoFectin™ Max is a new lipid-based transfection reagent. This versatile transfection reagent has been tested and optimized for highly efficient transfection of a large collection of commonly used cell lines as well as many difficult-to-transfect cell lines. |
|
|
|
Advantages
- Equal to or greater transfection efficiency compared with Lipofectamine® 3000 in plasmid transfection (Figure 1).
- Superior transfection efficiency for a broad range of cell lines compared with Lipofectamine® 2000 (Figures 2 and 3).
- Equal to or greater transfection efficiency compared with Lipofectamine® 2000 in siRNA transfection (Figure 4).
- Low cytotoxicity (Figure 5).
- Does not require removal of serum or culture medium, or removal of medium after transfection.
- For overexpression, knockdown, knockout, as well as high-throughput applications
* Promotion is valid in the US & Canada only. Offer is only valid on purchases of EF014. Not valid on other EndoFectin transfection reagents. Promo code must be presented at the time of purchase. Not valid on previous purchases and cannot be combined with other discounts. Promotion ends August 31, 2021.
Experiment 1: Comparison of EndoFectin™ Max and Lipofectamine® 3000 in plasmid transfection
Experiment 2: Comparison of EndoFectin™ Max and Lipofectamine® 2000 in plasmid transfection
 |
| |
| Figure 3. Assessment of EndoFectin™ Max transfection efficiencies using GFP visualization. 16 commonly-used cell lines were transfected with a GFP-expressing plasmid using either EndoFectin™ Max or Lipofectamine® 2000 (LP-2000). Cells were visualized 48 hours post-transfection under phase contrast or fluorescence microscopy (GFP filter). Lipofectamine® is a trademark of Invitrogen. |
| |
Experiment 3: Comparison of EndoFectin™ Max and Lipofectamine® 2000 in siRNA transfection
| A |
B |
 |
| |
| Figure 4. Comparison of transfection of siRNA between EndoFectin™ Max and Lipofectamine® 2000, Cell lines H1299 (A) and HEK293 (B) were transfected with either a firefly luciferase-expressing plasmid (blue bars), or co-tranfected with a firefly luciferase-expressing plasmid and an anti-luciferase siRNA (red bars). Transfection efficiencies were assessed by luciferase activity (RLU). Lipofectamine® is a trademark of Invitrogen. |
Experiment 4: Comparison of EndoFectin™ Max and Lipofectamine® 2000 for cytotoxicity
 |
| |
| Figure 5. Comparison of cytotoxicity between EndoFectin™ Max and Lipofectamine® 2000. Lipofectamine® is a trademark of Invitrogen. |
Related Products
CRISPR-Fectin
Introducing CRISPR-Fectin™ Transfection Reagent
CRISPR-Fectin™ is optimized lipid-based transfection reagent for CRISPR-Cas9 ribonucleoprotein delivery. Compatible with our GeneHero™ Cas9 Nuclease.
Advantages
- High transfection efficiency for Cas9 nuclease and synthetic sgRNA
- Low toxicity to cells
- Cost effective with as low as $0.059 per transfection reaction
GeneHero™ Cas9 Nuclease genome modification in HEK293 cell line. Cas9 nuclease was co-transfected with synthetic sgRNA into the HEK293 cells using CRISPR-Fectin™ transfection reagent. Three different sgRNA targeting the HUWE gene were designed and transfected with Cas9 protein respectively. The HUWE fragments were amplified from genomic DNA and subjected to the T7 endonuclease I assay. Cleaved DNA bands are indicated by red arrows.
EndoFectin Expi293
EndoFectin™ Expi293 is a powerful new transfection reagent ideally suited for transfection of the suspension cell line Expi293F. Expi293F is the most commonly used suspension HEK293 cell line for transient expression to achieve high cell density. EndoFectin™ Expi293 provides greater transfection efficiency of Expi293 cells than Expifectamine 293 over a range of cell densities, and is available as either the reagent alone or as a complete kit with 3 accompanying solutions.
Advantages
- Specially designed for transfection of the widely-used suspension cell line Expi293F
- Greater transfection efficiency of Expi293F cells than Expifectamine™ 293 (Figure 1).
- Greater protein expression than Expifectamine™ 293 (Figure 2)
- Does not require removal of serum or culture medium, or changing of medium after transfection.
- For overexpression, knockdown, knockout, as well as high-throughput applications
Experiment 1: Comparison of EndoFectin™ Expi293 and Expifectamine™ 293 in plasmid transfection
| A |
 |
| |
| B |
 |
| |
| |
| Figure 1. Comparison of transfection efficiencies of the suspension cell line Expi293F between EndoFectin™ Expi293 and Expifectamine 293. Expi293F cells were cultured in 125 ml flasks and transfected with a GFP-expressing plasmid. Transfection efficiencies were quantitated as relative fluorescence units (RFU, A) and compared visually using a fluorescence microscope (B). |
Experiment 2: Comparison of EndoFectin™ Expi293 and Expifectamine™ 293 in protein expression
| A |
 |
| |
| B |
 |
| |
| Figure 2. Comparisons of secreted (A) and intracellular (B) protein expression in suspension cell line Expi293F between the EndoFectin™ Expi293 kit (GeneCopoeia) and the Expifectamine 293 kit (Thermo Fisher). A. Expi293F cells were transfected with a Gaussia luciferase-expressing plasmid. GeneCopoeia transfection solutions or ThermoFisher enhancers were added 16-18 hours after transfection. Gaussia luciferase expression was measured in a luminometer. B. Expi293F cells were transfected with a Firefly luciferase-expressing plasmid. GeneCopoeia transfection solution 3 or Thermo Fisher enhancers were added 16-18 hours after transfection. Firefly luciferase levels were measured in a lluminometer 48 hours after transfection. |
Related Products
EndoFectin HepG2
EndoFectin™ HepG2 is a new and potent reagent optimized for transfection of the difficult-to-transfect hepatocellular carcinoma cell line HepG2. EndoFectin™ HepG2 provides superior transfection efficiency of HepG2 cells compared with Lipofectamine® 3000 (Figure 1) and Lipofectamine® 2000 (Figure 2).
Advantages
- Specially formulated for the difficult-to-transfect hepatocellular carcinoma cell line HepG2
- Greater transfection efficiency of HepG2 cells compared with Lipofectamine® 3000 (Figure 1).
- Superior transfection efficiency of HepG2 cells compared to Lipofectamine® 2000 (Figure 2)
- Transfection efficiency of HepG2 cells is comparable to electroporation, allowing you to achieve ultra-high levels of transfection more conveniently (Figure 3).
- Does not require removal of serum or culture medium or removal of medium after transfection.
Experiment 1: Comparison of EndoFectin™ HepG2 and Lipofectamine® 3000
 |
| |
|
Figure 1. Transfection of HepG2 cells using either EndoFectin™ Max, Lipofectamine® 2000 (LP2000) or Lipofectamine® 3000 (LP3000). Cells were transfected with a firefly luciferase-expressing plasmid. Transfection efficiencies were assessed by luciferase activity (RLU). Note: 0.15 uL/well of Lipofectamine® 3000 was used rather than 0.2 uL/well. Lipofectamine® is a trademark of Invitrogen. |
Experiment 2: Comparison of EndoFectin™ HepG2 and Lipofectamine® 2000
Figure 2. Comparison of transfection efficiencies of HepG2 cells between EndoFectin™ HepG2 and Lipofectamine® 2000 (LP2000). Top: Cells were transfected with a plasmid expressing luciferase, and quantitated in a luminometer. Bottom: HepG2 cells were transfected with a plasmid expressing GFP, and visualized using either visible light or fluorescence.
Experiment 3: Comparison of EndoFectin™ HepG2 and electroporation
EndoFectin™ HepG2 can also provide nearly as high transfection efficiency as electroporation, meaning that you can achieve ultra-high levels of transfection with much more convenience (Figure 3).
Figure 3. Comparison of transfection efficiencies of HepG2 cells between EndoFectin™ HepG2 and electroporation. HepG2 cells were electroporated with a plasmid expressing GFP, and visualized using either visible light or fluorescence.
Note: Lipofectamine® is a registered trademark of Invitrogen
.
Related Products
EndoFectin Lenti
EndoFectin™ Lenti is a robust transfection reagent, optimized specifically for lentiviral packaging. This cation-based transfection reagent delivers high transfection efficiency and high titer lentiviral packaging results, equal to or better than leading competitors (Figure 1).
Figure 1. HEK293T cells were transfected with an EGFP-expressing plasmid using various transfection reagents as indicated. The cells were observed with an inverted fluorescence microscope 20 hours after transfection. HEK293T cells were transfected either in serum-free medium (A) or in 10% serum (B). Lipofectamine 2000® (LF2000) is a trademark of Invitrogen; FuGENE® is a trademark of Roche.
Related Products
